相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Pau Montesinos et al.
LEUKEMIA (2021)
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2021)
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Stephen M. Ansell et al.
CLINICAL CANCER RESEARCH (2021)
The SIRPα-CD47 immune checkpoint in NK cells
Tobias Deuse et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Emily Y. Jen et al.
CLINICAL CANCER RESEARCH (2020)
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
Elise Fournier et al.
BLOOD (2020)
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
Anne Sophie Kubasch et al.
LEUKEMIA (2020)
Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice
Yang Li et al.
NATURE COMMUNICATIONS (2020)
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Mark P. Chao et al.
FRONTIERS IN ONCOLOGY (2020)
CD34+CD38-CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
Francois Vergez et al.
CANCERS (2020)
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
Laurene Fenwarth et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results
Junyuan Qi et al.
BLOOD (2020)
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
S. Haubner et al.
LEUKEMIA (2019)
THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS
R. Advani et al.
HEMATOLOGICAL ONCOLOGY (2019)
Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas
Salvia Jain et al.
BLOOD (2019)
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
Ugo Testa et al.
CANCERS (2019)
A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results
Amer M. Zeidan et al.
BLOOD (2019)
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
David A. Sallman et al.
BLOOD (2019)
Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia
Bowen Yan et al.
LEUKEMIA (2019)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
Penka S. Petrova et al.
CLINICAL CANCER RESEARCH (2017)
Tracing the origins of relapse in acute myeloid leukaemia to stem cells
Liran I. Shlush et al.
NATURE (2017)
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
Nan Guo Ring et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
E. C. Pietsch et al.
BLOOD CANCER JOURNAL (2017)
SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells
Laia Pascual Ponce et al.
ONCOTARGET (2017)
Light transmission aggregometry using pre-coated microtiter plates and a Victor X5 plate reader
Pernille Just Vinholt et al.
PLOS ONE (2017)
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
Fabiana Perna et al.
CANCER CELL (2017)
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
C. Krupka et al.
LEUKEMIA (2016)
SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells
Emily C. Piccione et al.
CLINICAL CANCER RESEARCH (2016)
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Kipp Weiskopf et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
Emily C. Piccione et al.
MABS (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging
Binje Vick et al.
PLOS ONE (2015)
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Jie Liu et al.
PLOS ONE (2015)
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
Christina Krupka et al.
BLOOD (2014)
Signal-regulatory protein α from the NOD mouse binds human CD47 with an exceptionally high affinity - implications for engraftment of human cells
Lai Shan Kwong et al.
IMMUNOLOGY (2014)
Polymorphisms in the Human Inhibitory Signal-regulatory Protein α Do Not Affect Binding to Its Ligand CD47*
Deborah Hatherley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC
S. J. Busfield et al.
LEUKEMIA (2014)
Crystallization and preliminary X-ray diffraction analysis of the interleukin-3 alpha receptor bound to the Fab fragment of antibody CSL362
Sophie E. Broughton et al.
ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS (2014)
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
Diane Tseng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Kipp Weiskopf et al.
SCIENCE (2013)
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Roland B. Walter et al.
BLOOD (2012)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
Francois Vergez et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R gamma c-deficient mice
Jean-Emmanuel Sarry et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction
Xi Wen Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome
Annika Dufour et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia
Tobias Benthaus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Inhibition of self engulfment through deactivation of myosin-II at the phagocytic synapse between human cells
Richard K. Tsai et al.
JOURNAL OF CELL BIOLOGY (2008)
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
Fumihiko Ishikawa et al.
NATURE BIOTECHNOLOGY (2007)
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors
Pearlie K. Epling-Burnette et al.
BLOOD (2007)
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
DC Taussig et al.
BLOOD (2005)
Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family
G Brooke et al.
JOURNAL OF IMMUNOLOGY (2004)
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
VHJ van der Velden et al.
BLOOD (2001)
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
CT Jordan et al.
LEUKEMIA (2000)
Role of CD47 as a marker of self on red blood cells
PA Oldenborg et al.
SCIENCE (2000)
分享论文
